Notably, administration of anti-PD-L1 antibody in combination with HSP90 inhibitor ganetespib showed significantly higher anti-tumor activity than when treated with anti-PD-L1 alone in syngeneic mouse models of melanoma and colon carcinoma (167). This evidence concerns the gene HSP90AA1 and melanoma.